Meta-Analysisvery high evidence
Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY).
Lancet (London, England)·June 13, 2026·PMID 42248158
Why it mattersThis analysis provides robust, high-level evidence that finerenone offers kidney and cardiovascular protection across a broad CKD population, including those without diabetes and with varying eGFR and albuminuria levels, supporting its role as a foundational therapy in CKD management.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled